Floatz logo

Evogliptin

Chronic Hepatitis B With Significant Hepatic Fibrosis With Type 2 Diabetes

Seung Up KimSmall moleculePhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

13 Active assets in the Chronic Hepatitis B With Significant Hepatic Fibrosis With Type 2 Diabetes cohort.

Asset / SponsorPhaseRating
Lamivudine
Yonsei University
Phase 4BBB
Entecavir
Beijing Continent Pharmaceutical Co, Ltd.
Phase 4BBB
TENOFOVIR DISOPROXIL FUMARATE
Ningbo No.2 Hospital
Phase 4BBB
Telbivudine
The Fifth People's Hospital of Suzhou
Phase 4BBB
Adefovir Dipivoxil
Asian-Pacific Alliance of Liver Disease, Beijing
Phase 4BB

View all 29 →

Same molecule, other indications

Evogliptin is also rated in:

fibrotic liver diseaseDormant
BB
Indicative ·
65 / 100
View asset →
type 2 diabetes mellitusDormant
BB
Indicative ·
65 / 100
View asset →
metabolic dysfunction-associated steatotic liver diseaseDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →